Background： Tat-interacting protein 30 （TIP30） has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer （BUC） has not been in...Background： Tat-interacting protein 30 （TIP30） has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer （BUC） has not been investigated. Therefore, herein, we investigated the expression of T1P30 protein in BUC and normal bladder mucosa and the clinical significance of TIP30 expression in the prognosis of BUC. Methods： We reviewed data from 79 cases of BUC and 15 adjacent tissue samples from 79 patients treated at our institution between 2004 and 2007. TIP30 expression was examined by immunohistochemistry. The relationship between TIP30 expression and tumor stage, histological grade, and survival was analyzed. Differences between groups were evaluated using the t-test or matched-pairs test, and differences in the survival rates were analyzed with the log-rank test. Results： TIP30 protein expression was significantly reduced in BUC tissue （t = -6.91, P 〈 0.05） compared with normal tissue samples, and in invasive bladder cancer （t = 10.89, P 〈 0.05） compared with superficial bladder cancer. TIP30 protein expression differed significantly among different differentiated groups classified either according to the World Health Organization （2004, F = 17.48, P 〈 0.01） or World Health Organization （1973, F = 10.68, P 〈 0.01）. TIP30 protein expression was significantly reduced in high-grade papillary urothelial carcinoma compared with papillary urothelial neoplasm of low malignant potential （P 〈 0.05） and low-grade papillary urothelial carcinoma （P 〈 0.05）. Meanwhile, TIP30 protein expression was significantly reduced in Grade 111 BUC, compared with Grade I （P 〈 0.05） and Grade 11 （P 〈 0.05）. Patients with low T1P30 expression showed a higher incidence of disease progression than those with high TIP30 expression （t - 2.63, P 〈 0.05）. Kaplan-Meier survival analysis showed a strong positive relationship between TIP30 expression and overall survival （OS） （x^2 = 17.29, P 〈 0.05）. Conclusions： TIP30 expression was associated with clinical tumor stage in BUC, suggesting that it might play an important role in disease progression. Furthermore, TIP30 might predict postoperative OS. Thus, its evaluation might be useful lbr predicting prognosis.展开更多
文摘Background： Tat-interacting protein 30 （TIP30） has been reported to be a tumor suppressor, with reduced or absent expression in various tumors. However, its role in bladder urothelial cancer （BUC） has not been investigated. Therefore, herein, we investigated the expression of T1P30 protein in BUC and normal bladder mucosa and the clinical significance of TIP30 expression in the prognosis of BUC. Methods： We reviewed data from 79 cases of BUC and 15 adjacent tissue samples from 79 patients treated at our institution between 2004 and 2007. TIP30 expression was examined by immunohistochemistry. The relationship between TIP30 expression and tumor stage, histological grade, and survival was analyzed. Differences between groups were evaluated using the t-test or matched-pairs test, and differences in the survival rates were analyzed with the log-rank test. Results： TIP30 protein expression was significantly reduced in BUC tissue （t = -6.91, P 〈 0.05） compared with normal tissue samples, and in invasive bladder cancer （t = 10.89, P 〈 0.05） compared with superficial bladder cancer. TIP30 protein expression differed significantly among different differentiated groups classified either according to the World Health Organization （2004, F = 17.48, P 〈 0.01） or World Health Organization （1973, F = 10.68, P 〈 0.01）. TIP30 protein expression was significantly reduced in high-grade papillary urothelial carcinoma compared with papillary urothelial neoplasm of low malignant potential （P 〈 0.05） and low-grade papillary urothelial carcinoma （P 〈 0.05）. Meanwhile, TIP30 protein expression was significantly reduced in Grade 111 BUC, compared with Grade I （P 〈 0.05） and Grade 11 （P 〈 0.05）. Patients with low T1P30 expression showed a higher incidence of disease progression than those with high TIP30 expression （t - 2.63, P 〈 0.05）. Kaplan-Meier survival analysis showed a strong positive relationship between TIP30 expression and overall survival （OS） （x^2 = 17.29, P 〈 0.05）. Conclusions： TIP30 expression was associated with clinical tumor stage in BUC, suggesting that it might play an important role in disease progression. Furthermore, TIP30 might predict postoperative OS. Thus, its evaluation might be useful lbr predicting prognosis.
